APA (7th ed.) Citation

Miyachi, M., Tsuchiya, K., Hosono, A., Ogawa, A., Koh, K., Kikuta, A., . . . Hosoi, H. (2019). Phase II study of vincristine, actinomycin-D, cyclophosphamide and irinotecan for patients with newly diagnosed low-risk subset B rhabdomyosarcoma: A study protocol. Medicine (Baltimore), 98(52), e18344. https://doi.org/10.1097/MD.0000000000018344

Chicago Style (17th ed.) Citation

Miyachi, Mitsuru, Kunihiko Tsuchiya, Ako Hosono, Atsushi Ogawa, Katsuyoshi Koh, Atsushi Kikuta, Junichi Hara, Satoshi Teramukai, and Hajime Hosoi. "Phase II Study of Vincristine, Actinomycin-D, Cyclophosphamide and Irinotecan for Patients with Newly Diagnosed Low-risk Subset B Rhabdomyosarcoma: A Study Protocol." Medicine (Baltimore) 98, no. 52 (2019): e18344. https://doi.org/10.1097/MD.0000000000018344.

MLA (9th ed.) Citation

Miyachi, Mitsuru, et al. "Phase II Study of Vincristine, Actinomycin-D, Cyclophosphamide and Irinotecan for Patients with Newly Diagnosed Low-risk Subset B Rhabdomyosarcoma: A Study Protocol." Medicine (Baltimore), vol. 98, no. 52, 2019, p. e18344, https://doi.org/10.1097/MD.0000000000018344.